Optics
← Today's headlines

4 sources checked · 2 source groups included · 1h ago

Still Watching

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.

2 Left2 Center0 Right
Still watching. Optics is waiting for a cleaner match before calling the split.

STILL WATCHING

As of May 21, 2026 at 12:04 PM, this is how Optics News reads the wording differences in this story.

What happened The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
The headline split One side frames it as "New Weight Loss Drug Retatrutide Delivers Stunning Results". The other frames it as "STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial".
Can I trust it? Yes. 4 sources checked across 2 bias buckets.

WHAT EACH SIDE EMPHASIZED

Left / center-leftNew Weight Loss Drug Retatrutide Delivers Stunning Results

NBC News · Center-left · News report

CenterEli Lilly says next-generation weight loss drug clears crucial obesity trial

CNBC · Center · News report

Right / center-rightNo matching source in this bucket yet.

Optics keeps watching for pickup.

SEE THE HEADLINES

C · CenterMostly Factual
CNBCNews report · May 21, 11:40 AM

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.

Open source
CL · Center-leftHigh
NBC NewsNews report · May 21, 12:04 PM

New Weight Loss Drug Retatrutide Delivers Stunning Results

retatrutidedeliversstunningresults

Remarkable new test results by drugmaker Eli Lilly reveal that their latest weight loss drug, retatrutide, may be even more effective than the three popular GLP-1s currently available. The...

Open source
CL · Center-leftHigh
The New York TimesNews report · May 21, 10:45 AM

Experimental Drug Yields Dramatic Weight Loss

People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.

Open source
C · CenterHigh
STAT NewsNews report · May 21, 10:45 AM

STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

statlillystriple-gleadsbariatric-surgery

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.

Open source
Details63/99 Wording Gap · Medium confidence · 4 sources
63/99 Wording GapMedium confidence4 sources · 2 bias bucketsLive match · 4 sources · 2 buckets · comparable news formatFormats: News report

SOURCE MAP CHANGES

May 21, 10:45 AM: STAT News joined the source map.

May 21, 10:45 AM: The New York Times joined the source map.

May 21, 11:40 AM: CNBC joined the source map.

May 21, 12:04 PM: NBC News joined the source map.

Now: Wording Gap is 63/99 and story health is live match · 4 sources · 2 buckets · comparable news format.